126 related articles for article (PubMed ID: 22214463)
1. Efficacy and safety of bevacizumab in glioblastomas.
De Fazio S; Russo E; Ammendola M; Donato Di Paola E; De Sarro G
Curr Med Chem; 2012; 19(7):972-81. PubMed ID: 22214463
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
Hanson JA; Hsu FP; Jacob AT; Bota DA; Alexandru D
Perm J; 2013; 17(4):68-74. PubMed ID: 24361023
[TBL] [Abstract][Full Text] [Related]
4. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
8. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
9. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
Khasraw M; Ameratunga M; Grommes C
Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
[TBL] [Abstract][Full Text] [Related]
11. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
14. ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution?
Addeo R; Perri F; Parlato C; Della Vittoria G
Curr Med Res Opin; 2014 Sep; 30(9):1871-3. PubMed ID: 24803042
[TBL] [Abstract][Full Text] [Related]
15. Use of bevacizumab in recurrent glioblastoma.
Ghiaseddin A; Peters KB
CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
[TBL] [Abstract][Full Text] [Related]
16. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for the treatment of glioblastoma.
Chowdhary S; Chamberlain M
Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
[TBL] [Abstract][Full Text] [Related]
19. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]